In a groundbreaking clinical milestone, the novel targeted RAS inhibitor daraxonrasib has demonstrated both safety and promising efficacy in a phase 1/2 trial involving patients with advanced pancreatic cancer harboring RAS mutations. This first-in-human study, spearheaded by researchers at the Dana-Farber Cancer Institute and collaborators nationwide, marks a significant advance against one of the most lethal malignancies known to modern medicine. Published in the prestigious New England Journal of Medicine, these findings pave the way for a pivotal phase 3 clinical trial, RASolute 302, which aims to directly compare daraxonrasib to standard second-line chemotherapy regimens in metastatic pancreatic cancer.
Pancreatic cancer is notorious for its late presentation and rapid progression, with most patients receiving a diagnosis only after the disease has metastasized, rendering surgical intervention infeasible. Historically, chemotherapy has been the cornerstone of treatment for these patients, yet survival rates remain dismal, with less than one year median overall survival and limited benefits from subsequent lines of therapy. The urgent need for novel, targeted therapeutics has driven extensive research into the molecular underpinnings of this aggressive tumor type.
KRAS mutations lie at the heart of pancreatic cancer pathogenesis, present in over 90% of cases, driving oncogenic signaling that fuels tumor growth and metastasis. For decades, KRAS was deemed “undruggable” due to its high affinity for GTP/GDP and lack of suitable binding pockets, thwarting traditional small molecule inhibition strategies. However, a paradigm shift occurred roughly ten years ago with the advent of covalent inhibitors targeting specific KRAS mutants, particularly KRAS G12C, which are more prevalent in lung and colorectal cancers but rare in pancreatic tumors.
Daraxonrasib distinguishes itself as a RAS(ON) multi-selective inhibitor that uniquely targets the spectrum of KRAS mutations commonly found in pancreatic cancer, including but not limited to G12D and G12V mutations. Mechanistically, daraxonrasib operates as a molecular glue that facilitates the stable association of mutant RAS proteins with cyclophilin A, a peptidyl-prolyl isomerase, thereby obstructing downstream RAS signaling pathways critical for tumor cell survival and proliferation. Administered orally as a daily pill, daraxonrasib offers a convenient route of administration for patients often burdened by intensive chemotherapy regimens.
Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research and lead investigator, emphasized the transformative potential of this agent, stating that daraxonrasib could become a broadly applicable targeted therapy for nearly all patients with advanced pancreatic cancer if ongoing and future clinical trials corroborate these initial results. The phase 1/2 trial enrolled 168 heavily pretreated patients, all harboring RAS mutations, most of whom had undergone one or more lines of chemotherapy prior to study enrollment.
Safety analysis revealed that while many patients experienced side effects—most commonly rash, mucositis, nausea, and diarrhea—these adverse events were generally manageable with supportive care. The tolerability profile of daraxonrasib proved favorable, facilitating sustained treatment adherence, which is paramount in this fragile patient population. This safety and tolerability profile supports further development and intensification of phase 3 trials.
Efficacy endpoints offer a promising glimpse into daraxonrasib’s therapeutic activity. At the recommended phase 2 dose of 300 mg once daily, approximately 30% of patients with one prior line of therapy achieved an objective tumor response, a remarkable figure given the refractory nature of their disease. Even more encouragingly, roughly 90% of patients experienced disease control, defined as tumor shrinkage or stabilization, across all prior treatment strata. The median duration of response extended beyond eight months for patients with limited prior therapy, illustrating meaningful clinical benefit.
The RASolute 302 study, an ongoing randomized phase 3 trial, will rigorously assess whether daraxonrasib can supplant current second-line chemotherapy as the therapeutic standard. Designed to directly compare efficacy, progression-free survival, and overall survival, this trial represents a critical next step in validating RAS inhibition as a cornerstone of pancreatic cancer treatment. Dr. Wolpin’s upcoming plenary presentation at the 2026 American Society for Clinical Oncology Annual Meeting is highly anticipated by the oncology community.
Crucially, daraxonrasib heralds not only a novel therapeutic agent but symbolizes a paradigm shift in targeting the RAS oncogene, historically one of the most challenging molecular targets in oncology. Its multi-selective activity across prevalent pancreatic cancer RAS mutations and its unique mechanism disrupting RAS-cyclophilin A interaction distinguish it from earlier mutation-specific inhibitors that have limited scope in this tumor type.
The pursuit of mutant RAS inhibition embodies years of concerted efforts from chemists, molecular biologists, oncologists, and patient advocates, culminating in this innovative approach that transforms a previously “undruggable” target into a viable therapeutic vulnerability. This evolving class of RAS inhibitors, including several other candidates now entering clinical trials, may soon redefine treatment algorithms for pancreatic and other RAS-driven cancers.
While considerable challenges remain—including optimizing combination therapies, overcoming resistance mechanisms, and managing long-term toxicities—daraxonrasib’s success signals a new dawn in pancreatic cancer therapy. It offers renewed hope that targeted inhibition of a fundamental oncogenic driver can translate to durable responses and improved survival outcomes for patients afflicted with this devastating disease.
Funding for this research was provided by Revolution Medicines, underscoring the critical collaboration between academic investigators and industry partners in advancing translational oncology. The Dana-Farber Cancer Institute continues to lead innovation in cancer research and treatment, aiming to transform scientific breakthroughs into life-extending therapies for patients worldwide.
Subject of Research: Targeted inhibition of RAS mutations in advanced pancreatic cancer
Article Title: Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
News Publication Date: 7-May-2026
Web References: https://www.nejm.org/doi/full/10.1056/NEJMoa2505783
References: New England Journal of Medicine, DOI: 10.1056/NEJMoa2505783
Image Credits: Dana-Farber Cancer Institute
Keywords: Pancreatic cancer, RAS mutation, KRAS, daraxonrasib, targeted therapy, molecular glue, clinical trial, phase 1/2, phase 3, RASolute 302, oncology, new drug development
Tags: advanced pancreatic cancer treatmentDana-Farber Cancer Institute studyKRAS mutation targeted therapymetastatic pancreatic cancer researchnovel targeted cancer therapeuticsoncogenic KRAS signaling inhibitionpancreatic cancer molecular pathogenesisphase 1/2 clinical trialRAS inhibitor daraxonrasibRASolute 302 phase 3 trialsafety and efficacy in oncology trialssecond-line chemotherapy alternatives
